Suppr超能文献

纳米颗粒靶向动脉粥样硬化病变中的内膜巨噬细胞。

Nanoparticles target intimal macrophages in atherosclerotic lesions.

机构信息

Department of Nutritional Sciences, Texas Tech University, Lubbock, TX, USA.

Department of Chemistry, Texas Tech University, Lubbock, TX, USA.

出版信息

Nanomedicine. 2021 Feb;32:102346. doi: 10.1016/j.nano.2020.102346. Epub 2020 Nov 29.

Abstract

Oxidized phosphatidylcholines (oxPCs) enriched on the oxidized LDL (oxLDL) surface are responsible ligands for binding oxLDL to the CD36 receptor of intimal macrophages in atherosclerotic lesions. We synthesized liposome-like nanoparticles (NPs) using soy phosphatidylcholine and incorporated 1-palmitoyl-2-(4-keto-dodec-3-enedioyl) phosphatidylcholine, a type of oxPCs, on their surface to make ligand-NP (L-NPs). The objectives of this study were to measure and compare their binding affinity to and uptake by primary mouse and THP-1 derived macrophages, and to determine their target specificity to intimal macrophages in aortic lesions in LDL receptor null (LDLr-/-) mice. All in vitro data demonstrate that L-NPs had a high binding affinity to macrophage CD36 receptor. L-NPs had 1.4-fold higher accumulation in aortic lesion areas than NPs. L-NPs co-localized with intimal macrophages and CD36 receptors in the aortic lesions. This target delivery approach may portend a breakthrough in molecular imaging and targeted treatment of atherosclerosis.

摘要

氧化磷脂酰胆碱(oxPCs)在氧化 LDL(oxLDL)表面富集,是 oxLDL 与动脉粥样硬化病变中内膜巨噬细胞 CD36 受体结合的配体。我们使用大豆磷脂酰胆碱合成了类脂质体纳米颗粒(NPs),并在其表面掺入了 1-棕榈酰基-2-(4-酮-十二烷-3-烯酰基)磷脂酰胆碱,即一种 oxPCs,制成配体-NP(L-NPs)。本研究的目的是测量并比较其与原代小鼠和 THP-1 衍生巨噬细胞的结合亲和力和摄取率,并确定其在 LDL 受体缺失(LDLr-/-)小鼠主动脉病变中内膜巨噬细胞的靶向特异性。所有体外数据均表明 L-NPs 与巨噬细胞 CD36 受体具有高结合亲和力。L-NPs 在主动脉病变区域的积累量比 NPs 高 1.4 倍。L-NPs 在主动脉病变中与内膜巨噬细胞和 CD36 受体共定位。这种靶向递药方法可能预示着在动脉粥样硬化的分子成像和靶向治疗方面取得突破。

相似文献

1
Nanoparticles target intimal macrophages in atherosclerotic lesions.
Nanomedicine. 2021 Feb;32:102346. doi: 10.1016/j.nano.2020.102346. Epub 2020 Nov 29.
2
Detection of atherosclerotic lesions and intimal macrophages using CD36-targeted nanovesicles.
J Control Release. 2015 Dec 28;220(Pt A):61-70. doi: 10.1016/j.jconrel.2015.10.004. Epub 2015 Oct 9.
3
Anti-atherogenic effects of CD36-targeted epigallocatechin gallate-loaded nanoparticles.
J Control Release. 2019 Jun 10;303:263-273. doi: 10.1016/j.jconrel.2019.04.018. Epub 2019 Apr 15.
7
Salvianolic acid B inhibits macrophage uptake of modified low density lipoprotein (mLDL) in a scavenger receptor CD36-dependent manner.
Atherosclerosis. 2012 Jul;223(1):152-9. doi: 10.1016/j.atherosclerosis.2012.05.006. Epub 2012 May 15.
9
CD36 is a receptor for oxidized low density lipoprotein.
J Biol Chem. 1993 Jun 5;268(16):11811-6.
10
Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36.
J Biol Chem. 2002 Oct 11;277(41):38503-16. doi: 10.1074/jbc.M203318200. Epub 2002 Jul 8.

引用本文的文献

1
How Advanced Is Nanomedicine for Atherosclerosis?
Int J Nanomedicine. 2025 Mar 17;20:3445-3470. doi: 10.2147/IJN.S508757. eCollection 2025.
3
Pluronic F127/lecithin PLGA nanoparticles as carriers of monocyte-targeted jakinibs: a potential therapeutic platform.
Nanomedicine (Lond). 2025 Jan;20(1):9-22. doi: 10.1080/17435889.2024.2415877. Epub 2024 Oct 29.
5
Targeted Delivery of Nanoparticles to Blood Vessels for the Treatment of Atherosclerosis.
Biomedicines. 2024 Jul 6;12(7):1504. doi: 10.3390/biomedicines12071504.
6
Advances in the treatment of atherosclerosis with ligand-modified nanocarriers.
Exploration (Beijing). 2023 Dec 7;4(3):20230090. doi: 10.1002/EXP.20230090. eCollection 2024 Jun.
7
PLGA-LEC/F127 hybrid nanoparticles loaded with curcumin and their modulatory effect on monocytes.
Nanomedicine (Lond). 2024 Jun 20;19(15):1407-1423. doi: 10.1080/17435889.2024.2357530. Epub 2024 Jun 26.
9
Molecular Imaging of Matrix Metalloproteinase-2 in Atherosclerosis Using a Smart Multifunctional PET/MRI Nanoparticle.
Int J Nanomedicine. 2022 Dec 28;17:6773-6789. doi: 10.2147/IJN.S385679. eCollection 2022.
10
Targeting and delivery of microRNA-targeting antisense oligonucleotides in cardiovascular diseases.
Atherosclerosis. 2023 Jun;374:44-54. doi: 10.1016/j.atherosclerosis.2022.12.003. Epub 2022 Dec 19.

本文引用的文献

1
Detection of atherosclerotic lesions and intimal macrophages using CD36-targeted nanovesicles.
J Control Release. 2015 Dec 28;220(Pt A):61-70. doi: 10.1016/j.jconrel.2015.10.004. Epub 2015 Oct 9.
3
Polyethylene glycol-modified dendrimer-entrapped gold nanoparticles enhance CT imaging of blood pool in atherosclerotic mice.
Nanoscale Res Lett. 2014 Sep 26;9(1):529. doi: 10.1186/1556-276X-9-529. eCollection 2014.
4
Inflammation and its resolution as determinants of acute coronary syndromes.
Circ Res. 2014 Jun 6;114(12):1867-79. doi: 10.1161/CIRCRESAHA.114.302699.
5
Recent advances in the role of immunity in atherosclerosis.
Circ Res. 2013 Dec 6;113(12):e111-4. doi: 10.1161/CIRCRESAHA.113.302986.
6
Macrophages in atherosclerosis: a dynamic balance.
Nat Rev Immunol. 2013 Oct;13(10):709-21. doi: 10.1038/nri3520. Epub 2013 Sep 2.
7
Immune effector mechanisms implicated in atherosclerosis: from mice to humans.
Immunity. 2013 Jun 27;38(6):1092-104. doi: 10.1016/j.immuni.2013.06.009.
8
Mechanisms of acute coronary syndromes and their implications for therapy.
N Engl J Med. 2013 May 23;368(21):2004-13. doi: 10.1056/NEJMra1216063.
9
Polymeric nanoparticle PET/MR imaging allows macrophage detection in atherosclerotic plaques.
Circ Res. 2013 Mar 1;112(5):755-61. doi: 10.1161/CIRCRESAHA.111.300576. Epub 2013 Jan 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验